Navigation Links
Harmless virus may hold key to more effective HIV drug discovery

New phage display technique successful in identifying compounds that show potential to overcome drug resistance

A simple, harmless virus might hold the key to the more effective and efficient development of HIV and anti-viral drugs, UCI chemical biologists have found.

In order to better identify compounds that can outmaneuver a virus' effort to mutate and multiply, Gregory Weiss and Allison Olszewski employed this virus, called a bacteriophage, to learn how a HIV protein could respond to a new class of anti-viral molecules they have discovered.

By constantly mutating into new variations, HIV, in particular, has been very skillful at developing resistance to broad-spectrum methods to inhibit its expansion. Because of this, the development of effective HIV drugs has been difficult and expensive.

Weiss and Olszewski found that the bacteriophage can model millions of different mutational variants of an HIV protein called Nef. Knowing how the entire population of Nef variants responds to new drugs gives researchers greater ability to identify broad-spectrum, anti-HIV compounds. This approach, Weiss said, can make drug discovery efforts for other anti-viral therapies faster and more effective.

Study results appear in online version of the Journal of the American Chemical Society.

"Viruses are clever about mutating to defeat the best efforts of chemists and biologists," said Weiss, an assistant professor of chemistry and molecular biology and biochemistry. "By recruiting a harmless virus, we're learning how HIV will respond to new classes of anti-viral drugs before these compounds are tested in the clinic, which is currently an expensive and time-consuming process."

The Weiss laboratory specializes in developing massive libraries of proteins that can potentially target and bind to other proteins, using a process called phage display. In this study, Weiss and Olszewski first created one such library by attaching the Ne f protein onto the bacteriophage, which was then coaxed into synthesizing the millions of mutational variants of Nef. The researchers then targeted this library, which they call an allelome, with a second library of small-molecule compounds in order to identify the specific compounds that could target the entire population of Nef mutational variants. The results suggest chemically simpler, more flexible compounds could better accommodate viral mutations.

The research is part of a UCI program aimed at expanding the anti-HIV drug arsenal. The program includes National Academy of Sciences member Larry Overman in the Department of Chemistry, who together with co-workers synthesized the small-molecules used in the study. New anti-HIV compounds are being tested by Dr. W. Ed Robinson, Jr. in the Department of Pathology.

Weiss and Olszewski have made their method freely available to the scientific research community. Olszewski is a fourth-year graduate student in the Weiss laboratory. The study was largely supported by a Young Investigator Award to Weiss from the Beckman Foundation.


Source:University of California - Irvine

Related biology news :

1. Study: Harmless virus kills some cancers
2. Association of herpesvirus with lung disorder questioned
3. Topical treatment shown to inhibit HIV and herpes simplex virus infection
4. Elusive HIV shape change revealed; Key clue to how virus infects cells
5. Newly discovered virus linked to childhood lung disorders and Kawasaki disease
6. Live Recombinant Adenovirus Vaccine Technique Explored
7. Marburg virus disease in Angola - update
8. Studies reveal methods viruses use to sidestep immune system
9. Norovirus, AIDS vaccine and Hepatitis Virus
10. Epstein-Barr virus protein crucial to its role in blood cancers
11. Live vaccines more effective against horse herpes virus
Post Your Comments:

(Date:11/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), ... broader entry into the automotive market with a comprehensive ... pace of consumer electronics human interface innovation. Synaptics, industry-leading ... for the automotive industry and will be implemented in ... Europe , Japan , and ...
(Date:11/2/2015)... MENLO PARK, Calif. , Nov. 2, 2015 /PRNewswire/ ... to $9 million to provide preclinical development services to ... Under the contract, SRI will provide scientific expertise, modern ... a wide variety of preclinical pharmacology and toxicology studies ... --> --> The PREVENT Cancer Drug ...
(Date:10/29/2015)... Calif. , Oct. 29, 2015  The J. ... new report titled, "DNA Synthesis and Biosecurity: Lessons Learned ... the Department of Health and Human Services guidance for ... in 2010. --> ... it also has the potential to pose unique biosecurity ...
Breaking Biology News(10 mins):
(Date:11/27/2015)... 27, 2015 ... of companion diagnostics is one of the ... with pharmaceutical companies and diagnostic manufacturers working ... . --> ... on global cancer biomarkers market spread across ...
(Date:11/25/2015)... -- 2 nouvelles études permettent d , ... entre les souches bactériennes retrouvées dans la plaque ... . Ces recherches  ouvrent une nouvelle voie ... efficace de l,un des problèmes de santé les ...    --> 2 nouvelles études permettent d ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... of Black Aerospace Professionals (OPBAP) has been formalized with the signing of a ... leaders met with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, ...
(Date:11/24/2015)... ... , ... The United States Golf Association (USGA) today announced Dr. Bruce Clarke, ... annually since 1961, the USGA Green Section Award recognizes an individual’s distinguished service to ... Clarke, of Iselin, N.J., is an extension specialist of turfgrass pathology in the department ...
Breaking Biology Technology: